Target Corp – will turnaround be successful?

In my previous posts I was writing about WMT and AMZN. Now it is time for TGT. As you know at the end of January I bought 31 shares of Target @63.84. Well in my last analysis of TGT I wrote that “it is not a sexy story, but very cheap!”. In fact after weak results and...

Amazon – what can go wrong?

When holding both WMT and TGT in portfolio I think it is quite important to have a look on Amazon as well, so let’s have a look. First of all some financial data, to put business in context. Market cap is around $400b, net cash around $20b. As it comes to...

Wal-Mart – was Warren Buffett right?

Not far ago there was an information that Warren Buffett sold his stake in Wal-Mart. On Tuesday company presented very good results from Q4. Was Warren Buffett right with his selling decision? Well, it’s too short period of time to say that. Also I do not know the...

Coca-Cola – go defensive when market is high?

With S&P500 up by more than 5% year to date performance of KO, which is slightly negative doesn’t look like good. Keep in mind that KO is a typical defensive business, so risk of such investment is lower. Also when sentiment on the market is good then investors...

VF Corporation – quality matters!

It is my first earnings season with VF Corp, as I bought shares in mid-January 2017. Recalling, my key investment rationales were: high drawdown, 30% from the top 3% dividend yield + strong buybacks, acceptable return safe dividend payout of around 50% negative...

McDonald’s – again almost at all-time highs!

Recently I saw a movie The Founder, which inspired me to look again at McDonald. As we can read on Wikipedia about movie: This drama tells the true story of how Ray Kroc, a salesman from Illinois, met Mac and Dick McDonald, who were running a burger operation in 1950s...

Cardinal Health – give it a time!

Cardinal Health reacted very well on published financial results. Reminding, I was buying CAH not far ago, when there was uncertainty around drug prices and competitive war amongst drug distributors. So far so good performance, but let’s look on financial report. Here...

Gilead Sciences – 2017 will be tough…

I am an (un)fortunate shareholder of Gilead. Well truth to tell I was expecting business to decline, but guidance for 2017 is quite shocking and -10% reaction looks justified at first sight. Market was expecting around $10-12b in HCV Product Sales. What does it mean...

Archer Daniels Midland – how interpret Q4 results?

Yesterday ADM posted Q4 results and market reaction was at least strange. At the beginning share price dropped by more than 5% and then… went up to more than 2% profits. Such strange reaction made me think whether results were good or bad. Intuitively results were bad...

Cintas – will it grow forever?

Cintas is one of the companies, which share price performance I do not understand at all. Business is growing by single digit number and share price for the last five years is around +230%. This is mainly due to multiple expansion, but let’s have a look on...

AbbVie – a missed opportunity?

AbbVie is one of the cheapest companies in The Dividend Aristocrats spectrum when it comes to P/E and is offering one of the highest dividend yields. This is why company seems interesting to me. My current investable level is at $55, but when share price was at that...